CT-02
/ Captor Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 07, 2023
Captor Therapeutics Announces Three-Year Strategic Objectives
(GlobeNewswire)
- "Initiate the clinical development by Captor of its advanced projects CT-01 (Hepatocellular carcinoma) and CT-03 (haematological malignancies) in 2023 and 2024 respectively, with clinical data readouts in 2024 and 2025. Advance Captor's early pipeline assets in inflammation (CT-02, CT-05) to in-vivo proof of efficacy in 2023 as a prelude to collaborative development."
Clinical data • New trial • Preclinical • Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Immunology • Leukemia • Liver Cancer • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1